CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Azilsartan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02079805
NCT02079805Phase 4Completed
CompareCT.gov

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Takeda·interventional·Posted Mar 6, 2014·Updated Aug 2, 2017

In Brief

A Phase 4 clinical trial evaluating Azilsartan and Telmisartan for Essential Hypertension Complicated by Type 2 Diabetes Mellitus. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension Complicated by Type 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartJun 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago

Interventions

Azilsartandrug

Azilsartan tablets

Telmisartandrug

Telmisartan tablets